Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data

Study identification

• EU PAS number:
  EUPAS1000000344
• Study ID:
  1000000344
• Official title and acronym:
  Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The risk of anemia due to talazoparib is common and may be a barrier in its utilization and/or lead to premature treatment discontinuation. Successful prediction of this adverse event in patients receiving talazoparib is an important step in understanding and reducing the risk of such toxicities while maintaining patients on treatment through individualized patient-centered approaches such as more vigilant monitoring and early dose management. The primary goal of this study is to assess how well machine learning models predict anemia events before and after talazoparib dose modification. ; The objectives are: ; 1. Describe patient characteristics, dosing patterns and hemoglobin trajectories with respect to anemia events in talazoparib-treated metastatic castrate-resistant prostate cancer (mCRPC) patients from the TALAPRO-2 trial data; 2. Develop and evaluate machine learning prediction models of anemia risk after treatment initiation and preceding dose modification; ; 3. Develop and evaluate machine learning prediction models of anemia recovery after dose modification. This is a non-interventional (NI), observational, retrospective study with secondary data analysis of already existing clinical trial data. ; This study will use the existing TALAPRO-2 trial data of mCRPC patients allocated to the talazoparib + enzalutamide treatment arm and included in the safety analysis. ; A variety of machine learning models including LASSO Cox regression, extreme gradient boosting, survival support vector machine, and deep cox proportional hazards model will be applied to identify the best performing model for predicting anemia risk and recovery based on performance metrics such as concordance index (test c-index) and dynamic area under the curves (AUCs).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned:30/09/2024

Study start date

Planned:11/11/2024

Actual:02/12/2024

Data analysis start date

Actual:22/08/2024

Date of final study report

Planned:30/06/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only